# New leukemia clinical trials, last 30 days: 27 (2026)

Updated November 19, 2026.

27 new trials for leukemia were first posted on ClinicalTrials.gov in the 30 days from October 20, 2026 to November 18, 2026, as read on November 19, 2026.

## The full list

New leukemia clinical trials, last 30 days: 27 rows for $5, first posted from October 20, 2026 to November 18, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 4 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/new/leukemia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 27
- Recruiting or not yet: 27
- Read on: November 19, 2026

## Trials

The 25 newest of 27, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07945470 | Simulation-Free Single-Fraction Radiation Therapy for Indolent Lymphoma | University Health Network, Toronto | Not applicable | Recruiting | Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Mantle... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07945470) |
| November 18, 2026 | NCT07945236 | FISH Detection of PML::RARA and BCR::ABL1 | Assiut University | Observational | Not yet recruiting | Acute Promyelocytic Leukemia, Chronic Myeloid Leukemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07945236) |
| November 17, 2026 | NCT07940920 | A Personalised Anti-fatigue Program for Community-dwelling People With Chronic Lymphocytic Leukaemia | University of Surrey | Not applicable | Recruiting | Chronic Lymphocytic Leukemia, Fatigue Syndrome, Chronic | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940920) |
| November 16, 2026 | NCT07939971 | A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AML | TuHURA Biosciences, Inc. | Phase 1/2 | Not yet recruiting | Acute Myeloid Leukemia | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939971) |
| November 13, 2026 | NCT07937124 | An All-Oral Combination of Ivosidenib, Sonrotoclax, and Chidamide for Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation (ISC) | First Affiliated Hospital of Zhejiang University | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937124) |
| November 13, 2026 | NCT07936786 | HIIT-based Exercise Intervention for Improvement of Immunomodulatory, Cardiopulmonary, and Psychosocial Parameters During Maintenance... | University of Erlangen-Nürnberg Medical School | Not applicable | Not yet recruiting | Leukemia, HIIT, Sport | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936786) |
| November 10, 2026 | NCT07929740 | Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS | Kura Oncology, Inc. | Phase 1 | Not yet recruiting | Myelodysplastic Syndrome (MDS)/AML, Myeloid Leukemia, Acute | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929740) |
| November 9, 2026 | NCT07926607 | Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia | Second Affiliated Hospital of Nanchang University | Phase 1/2 | Not yet recruiting | Acute Myeloblastic Leukemia | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926607) |
| November 9, 2026 | NCT07925554 | Interferon-α Maintenance in Favorable-Risk AML | Peking University People's Hospital | Phase 2 | Recruiting | AML (Acute Myeloid Leukemia) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925554) |
| November 9, 2026 | NCT07925190 | A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 | Recruiting | Acute Myeloblastic Leukemia | 318 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925190) |
| November 6, 2026 | NCT07923071 | A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment | Syndax Pharmaceuticals | Phase 1 | Not yet recruiting | Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia, Refractory Leukemia, Relapsed Leukemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923071) |
| November 5, 2026 | NCT07919119 | Risk Stratification Value of Deep NGS-MRD Detection in Acute Myeloid Leukemia Patients After Allo-HSCT | Institute of Hematology & Blood Diseases Hospital, China | Observational | Not yet recruiting | Measurable Residual Disease, Acute Myeloid Leukemia | 169 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919119) |
| November 3, 2026 | NCT07912684 | The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized... | Gruppo Italiano Malattie EMatologiche dell'Adulto | Not applicable | Recruiting | Acute Myeloid Leukemia, Multiple Myeloma, Lymphoma | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912684) |
| November 2, 2026 | NCT07909733 | Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT | University of Wisconsin, Madison | Phase 1 | Not yet recruiting | High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation, Acute Myeloid Leukemia (AML), Chronic Myeloid... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909733) |
| October 29, 2026 | NCT07905183 | A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs | Enliven Therapeutics | Phase 3 | Not yet recruiting | Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive, Chronic Phase Chronic... | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905183) |
| October 29, 2026 | NCT07905027 | A Study of CLEC2A CAR T for Pediatric and Adult Patients With Relapsed or Refractory AML | Seattle Children's Hospital | Phase 1 | Not yet recruiting | Acute Myeloid Leukemia, Acute Myeloid Leukaemia Recurrent, Acute Myeloid Leukaemia Refractory | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905027) |
| October 29, 2026 | NCT07904884 | MAC vs RIC for Transplantation in FLT3-ITD-Mutated AML Guided by UHS-NGS MRD ( FLT3 - MAC vs RIC ) | First Affiliated Hospital of Zhejiang University | Not applicable | Not yet recruiting | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Acute Myeloid Leukemia | 310 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904884) |
| October 27, 2026 | NCT07899632 | A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors | Medsyn Biopharma, LLC | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899632) |
| October 27, 2026 | NCT07899398 | A Trial to Evaluate the Efficacy and Safety of a Fitness-adapted Thera-py Approach With Either Continuous Zanubrutinib Monotherapy or... | German CLL Study Group | Phase 2 | Not yet recruiting | CLL (Chronic Lymphocytic Leukemia) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899398) |
| October 27, 2026 | NCT07898488 | Glycemic Control in Leukemia Patients | Assiut University | Observational | Not yet recruiting | Leukemia | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898488) |
| October 27, 2026 | NCT07898436 | Menin Inhibitors in Pediatric Relapsed or Refractory Acute Leukemia | University Hospital, Strasbourg, France | Observational | Recruiting | Acute Leukemia, Relapsed or Refractory Pediatric Leukemia, KMT2A-rearranged, NUP98-rearranged, or NPM1-mutated... | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898436) |
| October 27, 2026 | NCT07897136 | CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Acute Myeloid Leukemia (AML), Relapsed/Refractory Acute Myeloid Leukemia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897136) |
| October 26, 2026 | NCT07895901 | Characterization of CD180 Protein Expression in Myeloid Hematological Malignancies by Flow Cytometry | University Hospital, Strasbourg, France | Observational | Recruiting | Acute Myeloid Leukemia, Myeloid Hematological Malignancies, Normal Hematopoietic Stem and Progenitor Cells | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895901) |
| October 23, 2026 | NCT07891468 | huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers | University of Pennsylvania | Phase 1 | Not yet recruiting | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Richter's Transformation | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891468) |
| October 21, 2026 | NCT07887061 | Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic... | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887061) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 6 |
| Phase 1/2 | 3 |
| Phase 2 | 4 |
| Phase 3 | 3 |
| Not applicable | 5 |
| Observational | 6 |

## Sponsors posting most

| Sponsor | Trials |
| --- | --- |
| Assiut University | 2 |
| First Affiliated Hospital of Zhejiang University | 2 |
| University Hospital, Strasbourg, France | 2 |
| University Health Network, Toronto | 1 |
| University of Surrey | 1 |
| TuHURA Biosciences, Inc. | 1 |
| University of Erlangen-Nürnberg Medical School | 1 |
| Kura Oncology, Inc. | 1 |
| Second Affiliated Hospital of Nanchang University | 1 |
| Peking University People's Hospital | 1 |
| [Beijing InnoCare Pharma Tech Co., Ltd.](https://specstream.ai/data/clinical-trials/company/beijing-innocare-pharma-tech-co-ltd) | 1 |
| [Syndax Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/syndax-pharmaceuticals) | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 1 |
| University of Wisconsin, Madison | 1 |
| Enliven Therapeutics | 1 |
| Seattle Children's Hospital | 1 |
| Medsyn Biopharma, LLC | 1 |
| German CLL Study Group | 1 |
| University of Pennsylvania | 1 |
| Fred Hutchinson Cancer Center | 1 |
| [Jiangsu Hansoh Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hansoh-pharmaceutical-co-ltd) | 1 |
| Current Health | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Automation companies in the United States](https://specstream.ai/data/businesses/automation-companies/united-states)
- [Gastropubs in the United States](https://specstream.ai/data/businesses/gastropubs/united-states)
- [Pulmonology practices in the United States](https://specstream.ai/data/businesses/pulmonology-practices/united-states)
- [Bed and breakfasts in the United States](https://specstream.ai/data/businesses/bed-and-breakfasts/united-states)
- [Hydraulic repair companies in the United States](https://specstream.ai/data/businesses/hydraulic-repair-companies/united-states)
- [Software development companies in the United States](https://specstream.ai/data/businesses/software-development-companies/united-states)
